The news of Stifel maintaining a Buy rating and raising the price target for Kura Oncology is positive for the stock. This indicates that the analyst has confidence in the company's growth potential and expects the stock price to rise in the short term. The relevance and importance are high as the news directly pertains to KURA and is significant for investors. The confidence level is high as the information comes from a reputable analyst.